SCHEMBL1726623

SCHEMBL1726623

N#CC1C2CC3CC(C2)CC1C3

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12420559 1.00 CYP2C9 (0.38) CYP2C9
SCHEMBL12508912 1.00 CYP2C9 (0.38) CYP2C9
SCHEMBL21147695 1.00 CYP2C9 (0.38) CYP2C9
SCHEMBL10457153 0.73 CYP2C9 (0.42) CYP2C9
SCHEMBL12765620 0.73
SCHEMBL8781694 0.71
SCHEMBL13742599 0.69
SCHEMBL31167963 0.69
SCHEMBL4064503 0.69 CYP2C9 (0.38) CYP2C9
SCHEMBL871897 0.69 CYP2C9 (0.38) CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105906567-A Fungicidal N-Bicycloalkyl And N-Tricycloalkyl (Thio)Carboxamide Derivatives 拜耳知识产权有限责任公司 2016-08-31 CN claimed
JP-6040996-A None JP disclosed
JP-3072489-A None JP disclosed
EP-4614646-A1 SOLID ELECTROLYTE LAMINATE, SOLID SECONDARY BATTERY, AND PRODUCTION METHOD FOR SAME Nissan Motor Co., Ltd. (JP) 2025-09-10 EP disclosed
CN-120153508-A Solid electrolyte laminate, solid secondary battery, and method for producing same 日产自动车株式会社 2025-06-13 CN disclosed
WO-2024096065-A1 SOLID ELECTROLYTE LAMINATE, SOLID SECONDARY BATTERY, AND PRODUCTION METHOD FOR SAME 日産自動車株式会社 2024-05-10 WO disclosed
US-20230144767-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-05-11 US disclosed
CN-113121574-B Purine derivatives and their use in medicine 成都百裕制药股份有限公司 2023-02-17 CN disclosed
US-20210371460-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-12-02 US disclosed
US-20210371460-A1 TARGETED NITROXIDE AGENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2021-12-02 US disclosed
EP-0368946-B1 1,2-DIOXETANES TROPIX INC (US) 1994-09-14 EP disclosed
JP-H0640996-A INTERMEDIATE FOR PRODUCTION OF 1,2-DIOXETANE COMPOUND TROPIX INC 1994-02-15 JP disclosed
EP-0582317-A2 Synthesis of 1,2-dioxetanes and intermediates therefor TROPIX, INC. (US) 1994-02-09 EP disclosed
US-5177241-A SYNTHESIS OF 1,2-DIOXETANES AND INTERMEDIATES THEREFOR APPLIED BIOSYSTEMS, LLC 1993-01-05 US disclosed
JP-H0372489-A 1,2-DIOXETANE COMPOUND TROPIX INC 1991-03-27 JP disclosed
US-4956477-A Synthesis of 1,2-dioxetanes TROPIX, INC. (US) 1990-09-11 US disclosed
EP-0368946-A1 1,2-DIOXETANES. QUEST SYSTEMS INC (US) 1990-05-23 EP disclosed
EP-0368946-A4 1,2-DIOXETANES. QUEST SYSTEMS INC (US) 1990-05-14 EP disclosed
WO-1989006226-A1 SYNTHESIS OF 1,2-DIOXETANES AND INTERMEDIATES THEREFOR QUEST SYSTEMS, INC. (US) 1989-07-13 WO disclosed
EP-0178668-A2 Process for preparing rimantadine E.I. DU PONT DE NEMOURS AND COMPANY (US) 1986-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144767-A1 TARGETED NITROXIDE AGENTS TXNRD2, TXN2, HSPE1 CYP2C9 908/4885
US-20210371460-A1 TARGETED NITROXIDE AGENTS TXNRD2, TXN2, HSPE1 CYP2C9 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.